Cyclacel Pharmaceuticals (CYCC) Scheduled to Post Earnings on Tuesday

Posted by Latisha Jones on May 9th, 2024

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) is set to announce its earnings results after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of ($4.93) per share for the quarter.

Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last announced its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) EPS for the quarter, beating analysts’ consensus estimates of ($6.35) by $0.12. The firm had revenue of $0.03 million during the quarter. On average, analysts expect Cyclacel Pharmaceuticals to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Cyclacel Pharmaceuticals Price Performance

Shares of CYCC opened at $2.32 on Thursday. The company has a market cap of $3.06 million, a PE ratio of -0.09 and a beta of 0.54. The firm has a 50-day moving average of $2.16 and a 200-day moving average of $3.41. Cyclacel Pharmaceuticals has a one year low of $1.30 and a one year high of $13.20.

Analyst Upgrades and Downgrades

CYCC has been the topic of several research analyst reports. StockNews.com started coverage on Cyclacel Pharmaceuticals in a research note on Thursday, May 2nd. They issued a “hold” rating on the stock. Roth Mkm cut their price target on Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating for the company in a report on Friday, May 3rd.

Get Our Latest Report on Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Company Profile

(Get Free Report)

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.